文献速递肝病消化道肿瘤与早癌

HES V2.0在检测肝细胞癌方面优于GALAD:美国一项3期生物标志物研究

HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
PubMed 文献 · Hepatology · 2024-06-19

该研究为前瞻性样本采集、回顾性盲法评估的3期生物标志物队列研究,纳入2331例接受影像学和甲胎蛋白监测的肝硬化患者,其中125例发生肝细胞癌(71%为早期)。在固定假阳性率10%下,HES V2.0对任何期及早期肝细胞癌的真阳性率/灵敏度在多个时间点均高于GALAD和ASAP评分。

要点

  • HES V2.0对任何期HCC的真阳性率总体较GALAD提高7.2%,在诊断前6、12、24个月分别提高3.6%、7.2%、13.0%。
  • HES V2.0对早期HCC的灵敏度/真阳性率总体较GALAD提高6.7%,12个月和24个月分别提高6.3%和14.6%,但6个月无提高(+0.0%)。
  • HES V2.0对任何期和早期HCC的真阳性率在所有时间点均高于ASAP(分别提高5.9%至12.0%和13.4%至18.0%)。

核心结论

  • 在前瞻性队列研究中,HES V2.0识别新发肝细胞癌(包括早期)的性能显著高于GALAD或ASAP。

研究设计与样本

  • 研究为前瞻性样本采集、回顾性盲法评估的3期生物标志物队列研究,纳入接受影像学和甲胎蛋白监测的肝硬化患者。
  • 共分析2331例患者,其中125例发生肝细胞癌,71%处于早期。

主要发现

  • 在固定假阳性率10%下,HES V2.0对任何期HCC的真阳性率总体较GALAD提高7.2%,诊断前6、12、24个月分别提高3.6%、7.2%、13.0%。
  • HES V2.0对任何期HCC的真阳性率在所有时间点均高于ASAP,提高5.9%至12.0%。
  • HES V2.0对早期HCC的灵敏度/真阳性率总体较GALAD提高6.7%,12个月和24个月分别提高6.3%和14.6%,但6个月无提高(+0.0%)。
  • HES V2.0对早期HCC的灵敏度/真阳性率在所有时间点均高于ASAP,提高13.4%至18.0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The original hepatocellular carcinoma early detection screening (HES) score, which combines alpha-fetoprotein (AFP) with age, alanine aminotransferase, and platelets, has better performance than AFP alone for early HCC detection. We have developed HES V2.0 by adding AFP-L3 and des-gamma-carboxy prothrombin to the score and compared its performance to GALAD and ASAP scores among patients with cirrhosis. APPROACH AND RESULTS: We conducted a prospective-specimen collection, retrospective-blinded-evaluation phase 3 biomarker cohort study in patients with cirrhosis enrolled in imaging and AFP surveillance. True-positive rate (TPR)/sensitivity and false-positive rate for any or early HCC were calculated for GALAD, ASAP, and HES V2.0 scores within 6, 12, and 24 months of HCC diagnosis. We calculated the AUROC curve and estimated TPR based on an optimal threshold at a fixed false-positive rate of 10%. We analyzed 2331 patients, of whom 125 developed HCC (71% in the early stages). For any HCC, HES V2.0 had higher TPR than GALAD overall (+7.2%), at 6 months (+3.6%), at 12 months (+7.2%), and 24 months (+13.0%) before HCC diagnosis. HES V2.0 had higher TPR than ASAP for all time points (+5.9% to +12.0%). For early HCC, HES V2.0 had higher sensitivity/TPR than GALAD overall (+6.7%), at 12 months (+6.3%), and 24 months (+14.6%) but not at 6 months (+0.0%) and higher than ASAP for all time points (+13.4% to +18.0%). CONCLUSIONS: In a prospective cohort study, HES V2.0 had a significantly higher performance for identifying new HCC, including early stage, than GALAD or ASAP.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. El-Serag HB, Jin Q, Tayob N, et al. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2024. PMID: 38899967. doi:10.1097/HEP.0000000000000953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。